Mesenchymal stem cells in veterinary medicine

2011 ◽  
Vol 2 (2) ◽  
pp. 58-62
Author(s):  
Rebecca Webster ◽  
Ben Herbert ◽  
Sinead Blaber ◽  
Graham Vesey
2017 ◽  
Vol 4 (3) ◽  
Author(s):  
Ana G. Serrato López ◽  
Juan J. Montesinos Montesinos ◽  
Santiago R. Anzaldúa Arce

Mesenchymal stem cells (MSCs) have been isolated from the endometrium of humans, mice, cows, pigs and ewes. Typically, these cells are detected in the deep regions of the endometrium, closer to the union with the myometrium. MSCs possess characteristics such as clonogenicity and multipotentiality since they can differentiate in vitro into adipogenic, chondrogenic and osteogenic lineages. These cells can be induced to differentiate in vitro not only into the mesodermal lineage but also into the endodermal and ectodermal lineages. Therefore, MSCs show a great regenerative capacity for various organs and tissues, including the endometrium. Some advantages of endometrial MSCs compared with other MSC sources are their immune modulating activity, their ease of obtainment, and the amount of sample that may be collected. The study of endometrial MSCs in domestic animals is a new and promising field because increasing our understanding of the physiology and biology of these cells may lead to a better understanding of the physiopathology of reproductive diseases, and the development of treatment methods for infertility problems. In other veterinary medicine fields, MSCs can be used for the treatment of autoimmune diseases, cardiac affections, musculoskeletal and articular lesions, muscle degeneration, type 1 diabetes, urinary tract diseases, neurodegenerative processes and tumours. Finally, MSCs are also an important clinical tool for tissue engineering and regenerative medicine. The aim of this review is to present an updated outlook of the knowledge regarding endometrial MSCs and their possible applications in veterinary medicine.Figure 1: Immunoregulatory ability of MSCs. MSCs regulate the functions of NK cells, dendritic cells (DC) and T lymphocytes. The immunosuppressive effect may occur through the secretion of different factors or through cellular contact (black arrows). The former pathway involves TGFß, HGF, IL-10, PGE2, and HLA-G5, whereas the latter pathway involves the products of IDO enzyme activity, PD-L1, HLA-G1, ICAM-I and VCAM-I. Pro-inflammatory cytokines (IFN-?) secreted by NK cells and activated T lymphocytes favour the immunoregulatory activity of MSCs (dotted lines), because they increase or induce the secretion of molecules that regulate the functions of the distinct cellular components of the immune system. Modified from Montesinos et al, and Ma et al.19,66


2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Tania Sultana ◽  
Soojung Lee ◽  
Hun-Young Yoon ◽  
Jeong Ik Lee

Stem cell therapy has prompted the expansion of veterinary medicine both experimentally and clinically, with the potential to contribute to contemporary treatment strategies for various diseases and conditions for which limited or no therapeutic options are presently available. Although the application of various types of stem cells, such as bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose tissue-derived mesenchymal stem cells (AT-MSCs), and umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs), has promising potential to improve the health of different species, it is crucial that the benefits and drawbacks are completely evaluated before use. Umbilical cord blood (UCB) is a rich source of stem cells; nonetheless, isolation of mesenchymal stem cells (MSCs) from UCB presents technical challenges. Although MSCs have been isolated from UCB of diverse species such as human, equine, sheep, goat, and canine, there are inherent limitations of using UCB from these species for the expansion of MSCs. In this review, we investigated canine UCB (cUCB) and compared it with UCB from other species by reviewing recent articles published from February 2003 to June 2017 to gain an understanding of the limitations of cUCB in the acquisition of MSCs and to determine other suitable sources for the isolation of MSCs from canine. Our review indicates that cUCB is not an ideal source of MSCs because of insufficient volume and ethical issues. However, canine reproductive organs discarded during neutering may help broaden our understanding of effective isolation of MSCs. We recommend exploring canine reproductive and adipose tissue rather than UCB to fulfill the current need in veterinary medicine for the well-designed and ethically approved source of MSCs.


2017 ◽  
Vol 13 (Especial 2) ◽  
pp. 83-89
Author(s):  
Elaine Cristina Galhardo ◽  
Ariane Dantas ◽  
Aline Sousa Camargos ◽  
Fernanda da Cruz Landim

Mesenchymal Stem Cells (MSCs) are isolated from adult tissues and presents ability to originate identical cells or differentiate into specific tissue cells. Studies about in vitro culture and in vivo application of MSCs have pointed the potential to be explored in regenerative treatments and modulation of inflammatory processes, as well as the improvement of tissue engineering techniques and the development of biomaterials. Veterinary Medicine has presented, in several species, satisfactory results coming from the regenerative potential and paracrine activity characteristic of the MSCs. This review aimed, briefly showing promising results of the experimental MSCs application in Veterinary Medicine, its current biotechnological overview and general prospects.


Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1141
Author(s):  
Przemysław Prządka ◽  
Krzysztof Buczak ◽  
Ewelina Frejlich ◽  
Ludwika Gąsior ◽  
Kamil Suliga ◽  
...  

Regenerative medicine is a dynamically developing field of human and veterinary medicine. The animal model was most commonly used for mesenchymal stem cells (MSCs) treatment in experimental and preclinical studies with a satisfactory therapeutic effect. Year by year, the need for alternative treatments in veterinary medicine is increasing, and other applications for promising MSCs and their biological derivatives are constantly being sought. There is also an increase in demand for other methods of treating disease states, of which the classical treatment methods did not bring the desired results. Cell therapy can be a realistic option for treating human and animal diseases in the near future and therefore additional research is needed to optimize cell origins, numbers, or application methods in order to standardize the treatment process and assess its effects. The aim of the following work was to summarize available knowledge about stem cells in veterinary medicine and their possible application in the treatment of chosen musculoskeletal disorders in dogs and horses.


2021 ◽  
pp. 2588-2595
Author(s):  
Dwi Liliek Kusindarta ◽  
Hevi Wihadmadyatami

Umbilical cord blood (UCB) cells are an important source of mesenchymal stem cells (MSCs). It is known that the umbilical cord is rich in hematopoietic stem cells, which influenced research on ontogeny and transplantation (allogeneic transplantation). In recent years, stem cell research has emerged as an area of major interest due to its prospective applications in various aspects of both human and veterinary medicine. Moreover, it is known that the application of MSCs has several weaknesses. The use of these cells has limitations in terms of tumorigenesis effect, delivery, safety, and variability of therapeutic response, which led to the use of secretomes as an alternative to cell-free therapy. The main obstacle in its use is the availability of human UCB as an origin of MSCs and MSCs' secretomes, which are often difficult to obtain. Ethical issues regarding the use of stem cells based on human origin are another challenge, so an alternative is needed. Several studies have demonstrated that MSCs obtained from bovine umbilical cords have the same properties and express the same surface markers as MSCs obtained from human umbilical cords. Therefore, secretomes from MSCs derived from domestic animals (bovine) can possibly be used in human and veterinary medicine. This finding would contribute significantly to improve cell-free therapy. At present, the use of UCB MSCs derived from domestic animals, especially bovines, is very restricted, and only limited data about bovine UCB are available. Therefore, the aim of this review was to provide an updated overview of cell-free therapy and discuss the new possibilities introduced by the generation of this therapy derived from bovine umbilical MSCs as a promising tool in developing modern and efficient treatment strategies.


2017 ◽  
Vol 2017 ◽  
pp. 1-12 ◽  
Author(s):  
Takahiro Teshima ◽  
Hirotaka Matsumoto ◽  
Masaki Michishita ◽  
Akito Matsuoka ◽  
Maika Shiba ◽  
...  

Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are an attractive source for cell-based therapy of some diseases, including acute and chronic liver failure, in not only human medicine but also veterinary medicine. However, in veterinary medicine, no studies have reported the effects of AT-MSCs on liver injury in dogs. The purpose of this study was to investigate the effects of allogenic AT-MSCs on acute liver injury by carbon tetrachloride in dogs and to compare the therapeutic effects of AT-MSCs transplanted via the peripheral vein (PV) or splenic vein (SV). After transplantation of AT-MSCs through the PV or SV, serum liver enzymes were decreased significantly, and SV injection was more effective compared with PV injection. By comparing the number of engrafted AT-MSCs in the liver, SV injection was significantly more effective than PV injection. mRNA expression levels of proinflammatory cytokines, such as IL-1, IL-6, IL-8, and IFNγ, in the liver were decreased significantly, but those of anti-inflammatory cytokines, such as IL-4 and IL-10, HGF, and VEGFA, were significantly increased after the first AT-MSC injection. These findings suggest that allogenic AT-MSCs injected via the PV or SV ameliorate acute hepatic injury in dogs, and AT-MSCs injected via the SV provide more effective improvement.


Author(s):  
Gabrielle Rosemblit Martins ◽  
Maria Fátima da Silva Teixeira ◽  
Rosivaldo Quirino Beserra Junior ◽  
Ronaldo Pereira Dias ◽  
Tereza D'ávila de Freitas Aguiar ◽  
...  

2021 ◽  
Author(s):  
Svetlana Platonova ◽  
Daria Korovina ◽  
Ekaterina Viktorova ◽  
Irina Savchenkova

The application of animal mesenchymal stem cells has been actively studied in veterinary medicine over the past decade. In horses, the use of stem cells is mainly aimed at the treatment and maintenance of the musculoskeletal system. This review summarizes the currently published data on the therapeutic use of mesenchymal stem cells in equine tendon injuries. Tendon lesions are the most common cause of horse limp. It has been demonstrated that the use of mesenchymal stem cells compared with traditional methods of treatment can significantly reduce the re-injury. Currently, there are a large number of stem cell application protocol versions. Many researchers have obtained positive clinical results in using a combination of mesenchymal stem cells and platelet-rich blood plasma. Studies have demonstrated the safety of using allogeneic mesenchymal stem cells as an alternative to autologous. This review shows that the application of mesenchymal stem cells for horse tendon regeneration is a perspective area in veterinary medicine.


BIOCELL ◽  
2022 ◽  
Vol 46 (5) ◽  
pp. 1173-1176
Author(s):  
AMANDA BARACHO TRINDADE HILL ◽  
JONATHAN EDWIN BARACHO TRINDADE HILL

Sign in / Sign up

Export Citation Format

Share Document